Roche Partners with China Resource Medicine to Promote Xofluza in China
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into a partnership with China-based China Resource...
SWX: ROG
Roche Returns Global Rights to Blueprint’s RET Inhibitor Gavreto
US-based biotech Blueprint Medicines has announced that Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has...
Roche and HKSTP Collaborate to Boost Life Sciences in Greater Bay Area
Swiss pharmaceutical giant Roche (SWX: ROG) has signed a multi-faceted collaboration agreement with the Hong...
Roche’s Polivy Approved by China’s NMPA for Lymphoma Treatment
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the National Medical Products...
Roche’s Glofitamab and Dizal’s Sunvozertinib Enter Priority Review
The Center for Drug Evaluation (CDE) website indicates that Swiss giant Roche’s (SWX: ROG) glofitamab...
Roche and Zhongshan Hospital Collaborate on Clinical Studies and Innovation Center
Swiss giant Roche’s (SWX: ROG) China unit and Roche Diagnostics’ China unit entered into a...
Roche Reports Q3 Sales Growth, Hit by COVID-19 Product Decline
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2022 financial report last week, showing...
Bio-Thera’s BAT1806 Biosimilar Accepted for Review by European Medicine Agency
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that a Biologic License Application (BLA) for...
CSPC’s Generic Xofluza Gains NMPA Approval Amid Roche Patent Dispute
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has obtained market approval from the National...
Roche’s Subcutaneous Herceptin Approved in China for HER2-Positive Breast Cancer
Swiss pharmaceutical giant Roche’s (SWX: ROG) Herceptin (trastuzumab, subcutaneous injection) has been approved in China...
Roche Boosts China Investment with Additional RMB 250 Million
Swiss pharmaceutical giant Roche (SWX: ROG) has pledged to invest an additional RMB 250 million...